COLLABORATORS

MDM – Molecular Diversity of Microbes

MDM team research revolves around bacteria and their viruses, phages. Facing the abundance and diversity of their viruses, bacteria and archaea have developed multiple lines of defense that can be referred to as « prokaryotic immune systems« . Our research focuses on these anti-phage immune systems. We are trying to understand evolutionary patterns and molecular mechanisms of these systems but also how to use them for medical applications. We work at several scales: from computational genomic analysis on thousands of prokaryotic genomes to experimental molecular genetics and diverse microbiology tools.

      Contact

Aude Bernheim

PhD
Principal Investigator
Bacterial Genetics ; Phage
Biology; Genomics
@AudeBer
aude.bernheim@pasteur.fr 

https://mdmlab.fr/
Publications ; CV;  

 

Generare

Generare is a drug discovery platform using powerful computational tools & synthetic biology to
efficiently mine microbial genomes for novel bioactive molecules. The startup patents and licenses
high-potential novel molecules to the pharmaceutical industry.

      Team leaders

Vincent Libis, CSO

I am interested in using synthetic biology for therapeutic innovation. These days I work on developing methods to rapidly discover novel bioactive microbial metabolites. Molecules of this type play important roles in medicine and they are a key source of antibiotics, anticancer agents or immunosuppressants. I spend most of my time developing sequencing, bioinformatics and molecular biology methods but I also like to think about how we can involve the general public in helping to source new medicines through citizen science projects.

https://www.generare.bio/

vincent.libis@cri-paris.org

 

Guillaume Vandenesch, CEO

guillaume@generare.bio

 

baCta project

Laastix is revolutionizing the rubber industry by using cutting-edge synthetic biology techniques to efficiently and sustainably produce high-quality natural rubber.
By using engineered microorganisms, we are able to bypass traditional rubber tree cultivation and reduce the heavy environmental impact associated with traditional rubber production : no more deforestation or monoculture. We also decrease our global dependance to fossil fuels, as 50% of global rubber comes from oil. Our biosynthetic rubber not only has a lower carbon footprint, but the supply is also more reliable, local, and customizable to meet the specific needs of various industries.

      Contact

Mathieu Nohet

Mathieu discovered synthetic biology and its numerous applications during the Covid lockdown, while researching the technology and science behind the miraculous RNA vaccines.
Realizing the critical importance of extracting and transforming raw materials in a sustainable way, he decided to use synthetic biology to produce natural rubber and other polymers, to decrease our carbon footprint and reduce our dependence on oil.
Prior to Laastix, Mathieu co-founded Manty, a startup helping public administrations conceive and pilot public policies with data.

mathieu@bacta.life